Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK9 | P50750 | 12/20 | 0.41 |
| ▸ | CCNT1 | O60563 | 11/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | VCP | P55072 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18520551 | 0.90 | CDK9 (0.39) | CDK9CCNT1GRM2DHODHRORC | |
| SCHEMBL18520608 | 0.88 | GRM2 (0.34) | GRM2DHODHBRD4 | |
| SCHEMBL18520609 | 0.88 | DHODH (0.33) | GRM2DHODHBRD4 | |
| SCHEMBL18520428 | 0.87 | TSHR (0.33) | CDK9CCNT1BRD4 | |
| SCHEMBL18520610 | 0.82 | JAK2 (0.35) | BRD4 | |
| SCHEMBL18520517 | 0.78 | GRM2 (0.40) | GRM2DHODH | |
| SCHEMBL18520430 | 0.76 | PDK4 (0.45) | CDK9CCNT1 | |
| SCHEMBL18520705 | 0.76 | GRM2 (0.39) | GRM2DHODHBRD4 | |
| SCHEMBL18520426 | 0.76 | DHODH (0.39) | GRM2DHODH | |
| SCHEMBL18520542 | 0.75 | KDM4E (0.39) | GRM2DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10745356-B2 | Compositions and methods for treating tuberculosis | THE BROAD INSTITUTE, INC. (US) | 2020-08-18 | — | — | US | disclosed |
| US-20190284140-A1 | COMPOSITIONS AND METHODS FOR TREATING TUBERCULOSIS | THE BROAD INSTITUTE, INC. | 2019-09-19 | — | — | US | disclosed |
| US-10329257-B2 | Compositions and methods for treating tuberculosis | THE BROAD INSTITUTE, INC. (US) | 2019-06-25 | — | — | US | disclosed |
| WO-2017027768-A1 | COMPOSITIONS AND METHODS FOR TREATING TUBERCULOSIS | THE BROAD INSTITUTE, INC. (US) | 2017-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10745356-B2 | Compositions and methods for treating tuberculosis | C5, IFNG, TERT | CDK9 2227/4885CCNT1 1578/4885GRM2 4698/4885 |
| US-10329257-B2 | Compositions and methods for treating tuberculosis | C5, IFNG, TERT | CDK9 2227/4885CCNT1 1578/4885GRM2 4698/4885 |
| US-20190284140-A1 | COMPOSITIONS AND METHODS FOR TREATING TUBERCULOSIS | C5, IFNG, TERT | CDK9 2227/4885CCNT1 1578/4885GRM2 4698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.